Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND studyYoshikazu Kinoshita, Motoyasu Kusano, Mototsugu Kato et al.|Journal of Gastroenterology|2017Cited by 30
Mo1890 Safety, Tolerability and Efficacy of E6011, Anti-Human Fractalkine Monoclonal Antibody, in the First-in-Patient Study for Crohn's DiseaseKatsuyoshi Matsuoka, Takanori Kanai∥, Satoshi Tanida et al.|Gastroenterology|2016Cited by 3